RT @CCII_KU: The study is co-authored by CCII Associate Prof. Ken Takahashi. Read more about the Takahashi lab's research 👇. .

RT @CCII_KU: "Near-infrared photoimmunotherapy as a complementary modality to in situ vaccine (ISV) in a preclinical pancreatic cancer mode….

The study is co-authored by CCII Associate Prof. Ken Takahashi. Read more about the Takahashi lab's research 👇.

"Near-infrared photoimmunotherapy as a complementary modality to in situ vaccine (ISV) in a preclinical pancreatic cancer model".Enhancing ISV via enforced antigen release by local tumor destructive therapy.

RT @EMBO: New opportunities for life scientists in #Japan through an. agreement between EMBO and the Japan Science and Technology Agency @J….

We are permanently recruiting highly motivated students & postdocs. To find out what CCII labs are working on, visit our research page. #Immunology #Immunotherapy .

Congratulations to the CCII #PhD scholarship recipients for the academic year 2024:.Ryoma Kato .Yuki Sato .Koki Ichimaru.

RT @CCII_KU: Designed by renowned architect Tadao Ando, the new CCII building in #Kyoto has a total floorspace of 9500 m2 over 5 floors. I….

RT @NobelPrize: "This isn't just a cancer therapy, this is a way of liberating people from the burden of having this disease that can come….

RT @NobelPrize: Thumbs up! Tasuku Honjo, surrounded by his team at @univkyoto, immediately after hearing the public news he had received th….

Designed by renowned architect Tadao Ando, the new CCII building in #Kyoto has a total floorspace of 9500 m2 over 5 floors. It provides lab & office space for up to 300 scientists, research fellows, students & visitors. #Immunology #Immunotherapy .

RT @CCII_KU: @ScienceMagazine CCII's Kenji Chamoto & colleagues have recently published a perspective on the effectiveness of spermidine in….

RT @CCII_KU: The original research was published in @ScienceMagazine in 2022 by Muna Al-Habsi et al."Spermidine activates mitochondrial tri….

RT @CCII_KU: Researchers at CCII are investigating the possible use of spermidine in dealing with age-related immune pathologies as well as….

@ScienceMagazine CCII's Kenji Chamoto & colleagues have recently published a perspective on the effectiveness of spermidine in enhancing antitumor responses in aged animals in @TrendsCellBio .

Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.

The original research was published in @ScienceMagazine in 2022 by Muna Al-Habsi et al."Spermidine activates mitochondrial trifunctional protein and improves antitumor immunity in mice".

Researchers at CCII are investigating the possible use of spermidine in dealing with age-related immune pathologies as well as to enhance the efficacy of treatments that block the PD1 pathway in aged patients.#Immunology #Immunotherapy .

The longest follow up study of the efficacy of anti-PD1 & anti-CTLA4 has just been published in @NEJM .It shows outcomes for #melanoma patients 10 years after the first approved anti-PD1 therapy. #Immunology #immunotherapy .

RT @CCII_KU: The Center for Cancer #Immunotherapy & Immunobiology was established at Kyoto University by Prof. Tasuku Honjo, who serves as….